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Using real-time quantitative PCR, we monitored Wilms tumor gene 1 (WT1) expression from diagnosis to
hematopoietic stem cell transplantation (HSCT) in adult patients with cytogenetically normal acute
myelogenous leukemia (CN-AML) and FLT3-ITD and NPM1 mutations. The values at diagnosis were evaluated
in 104 patients. Data collected after induction chemotherapy were available for all patients, but only 68
patients were treated with HSCT. Signiﬁcant WT1 expression cut-offs were determined by receiver operation
characteristic curve analysis, and rates of overall survival (OS) and disease-free survival (DFS) were estimated.
WT1 decrement ratios (DR) at postinduction chemotherapy and at pre- and post-HSCT compared with the
diagnostic level were calculated. Higher WT1 expression at diagnosis, postinduction chemotherapy, and pre-
HSCT showed inferior OS (P ¼ .015, <.001, and .002) and DFS (P ¼ .006, <.001, and .003). The cut-offs were
determined at the median for diagnostic WT1 expression and at the 25% level from the top for other time
points excluding post-HSCT. The WT1 DR  1-log after induction chemotherapy showed superior OS and DFS
(P ¼ .009 and .002) andWT1 DR  1-log preceding HSCT also showed superior OS and DFS (P ¼ .009 and .003).
Results of WT1 DR were consistently applicable in each subgroup with higher (1.0) and lower (<1.0) WT1
expression at diagnosis and also in NPM1-wild-type/FLT3-ITDenegative CN-AML. The WT1 DR therefore
predicted survival outcomes after HSCT more accurately than did the diagnostic WT1 expression. WT1
expression may serve as a reliable marker for residual disease and WT1 DR as a prognostic indicator,
particularly in NPM1-wild-type/FLT3-ITDenegative CN-AML. These measures may be applied throughout the
course of treatment and even after HSCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION aberrant expression of BAALC [4,9], ERG, and MN1. Use of
Most patients with acute myelogenous leukemia (AML)
have at least 1 chromosomal aberration in their marrow
blasts at diagnosis. Several recurrent structural and numeric
cytogenetic aberrations have been identiﬁed, and many of
them are shown already to independently predict the like-
lihood of complete remission (CR), relapse, and overall
survival (OS) [1,2]. However, in 40% to 49% of adults with
AML and in 25% of children with AML, no microscopically
detectable chromosomal abnormality can be found. This
cytogenetically normal AML (CN-AML) is the largest cyto-
genetic subgroup of adult AML [2,3]. Although this group is
characterized as having intermediate risk, only 40% of
patients are believed to be long-term survivors [4]. This has
led to recognition of CN-AML as a highly heterogeneous
subgroup of AML and to identiﬁcation of several genetic
abnormalities with prognostic value. These include muta-
tions in FLT3 [5,6], NPM1 [7], CEBPA [8], and MLL genes andedgments on page 965.
equests: Hee-Je Kim, MD, PhD, Depart-
od and Marrow Transplantation Center,
of Medicine, The Catholic University of
ng, Seocho-gu, Seoul 137-070, Korea.
olic.ac.kr (H.-J. Kim).
2013 American Society for Blood and Marrow
13.03.013these markers may increase the accuracy in predicting
response to current therapy and may lead to improved
survival through development of risk-adaptive treatment
strategies [10,11].
Wilms tumor gene 1 (WT1), located on chromosome
11p13, encodes a transcriptional regulator with both acti-
vator and repressor capabilities. WT1 may behave as either
a tumor suppressor gene [12] or an oncogene. However, the
functional expression, protein isoforms, and target genes of
WT1may be cell type dependent [13]. Expression of theWT1
gene is detected in 75% to 100% of adults with AML, and
mutations in WT1 occur in 10% to 15% of patients with AML
[14,15]. Either mutation or overexpression of WT1 has
adverse implications for survival and relapse in AML, and
persistence of WT1 expression after treatment may serve as
a marker for minimal residual disease (MRD) [15-19].
Mutations in the Fms-like tyrosine kinase 3 (FLT3)
receptor gene, most commonly internal tandem duplica-
tions (ITDs), are frequently found in AML. Overexpression of
FLT3-ITD at diagnosis is predictive of adverse survival
outcomes [6,20,21]. In contrast, NPM1 mutation, the most
common single genetic abnormality, may be associated with
early blast cell clearance, better CR rates, and favorable OS
[22,23]. This association appears to be stronger when NPM1Transplantation.
Table 1
Serially CheckedWT1 Expression Levels from Diagnosis to Post-HSCT in CN-
AML patients
WT1 Expression
RQ-PCR Level
(WT1/ABL1)
P
At diagnosis (n ¼ 104) .038*
25% .250
50% (median) .951y
75% 3.833
At postinduction chemotherapy <.001*
25% .005
50% (median) .022
75% .156y
J.-H. Yoon et al. / Biol Blood Marrow Transplant 19 (2013) 958e966 959mutation is not accompanied by FLT3-ITD mutation [24].
However, patients in the largest subgroup of CN-AML are
both NPM1-wild-type and FLT3-ITD negative [25]. In this
group, no speciﬁc minimal residual marker has yet been
introduced.
The objectives of this study were to assess serial WT1
expression levels and WT1 decrement ratios (DR) in the
course of treatment in adult CN-AML. In addition, we aimed
to evaluate the prognostic value of WT1 expression as
a marker of residual disease and the importance of MRD
kinetics in predicting OS and DFS, speciﬁcally in the NPM1-
wild-type/FLT3-ITD- negative CN-AML.At pre-HSCT (n ¼ 68) .001*
25% .006
50% (median) .019
75% .050y
At post-HSCT (n ¼ 58) .144
25% .004
50% (median) .008
75% .020
Patient number of WT1 DR  1-log
At postinduction chemotherapy
(n ¼ 104)
64 (61.5%) <.001*z
At pre-HSCT (n ¼ 68) 46 (67.6%) .003*z
At post-HSCT (n ¼ 58) 44 (75.9%) .144
Number of patients with WT1 DR more than 1-log after treatments
compared with diagnostic level are also displayed.
* P signiﬁcant at the < .05 level.
y Statistically signiﬁcant cut-off levels of WT1 expression for both OS and
DFS were determined by ROC curve analysis. At diagnosis j 1.0 (median,
P¼ .038), at postinduction chemotherapyj .15 (25% from the top, P< .001),
at pre-HSCT j .050 (25% from the top, P ¼ .001).
z Value presenting the statistical signiﬁcance of WT1 DR more than 1-log
for OS and DFS analyzed by ROC curve analysis.METHODS
Patients
The Catholic Medical Center Institutional Review Board approved this
single-center retrospective study. Medical records were reviewed for 515
AML patients (ages 15 to 85 years; median, 45.2 years) with variable
karyotypes who were diagnosed from July 2008 to December 2011. CN-AML
was establishedmainly by chromosomal analysis yielding negative result for
multiplex PCR analysis. Normal karyotype was established in bone marrow
(BM) cells exclusively, after 24 and 48 hours in unsynchronized culture by
GTG banding in at least 20 metaphases. The International System for Cyto-
genetic Nomenclature was used as a guideline for classiﬁcation, and data on
206 CN-AML patients (40.0%) were available in this study.
Among the 206 patients with CN-AML, 181 had results of a FLT3-ITD
mutation analysis (positive in 46 patients [25.4%]), 184 had results of
a NPM1 mutation analysis (positive in 65 patients [35.3%]), and 125 had
results forWT1 expression at the time of diagnosis. Because we started each
marker examination at different time points, the sample size was reduced
and ﬁnally consisted of 104 patients with data available for all 3 molecular
markers (FLT3-ITD and NPM1 mutations and WT1 expression at the diag-
nostic and postinduction chemotherapy time points). Sixty-eight patients
were treated by hematopoietic stem cell transplantation (HSCT) and had
pre-HSCT data available; however, the post-HSCT data for 10 patients were
missing. Therefore, data at 1 month post-HSCT were available for only 58
patients.Molecular Marker Study
WT1 expression in BM samples were determined by real-time quanti-
tative PCR (RQ-PCR) using the WT1 ProﬁleQuant kit (Ipsogen, Marseille,
France). Data were analyzed for assays performed at diagnosis, post-
induction chemotherapy, and pre- and post-HSCT. The post-HSCT WT1
expression results were uniformly checked at approximately 1 month after
stem cell infusion. The FLT3-ITDmutationwas evaluated by multiplex allele-
speciﬁc PCR (ABSOLUTE FLT3 TKD/ITD PCR; Biosewoom, Korea), and the
NPM1 mutation and NPM1 expression were measured by RQ-PCR using the
NPM1 MutaQuant kit (Ipsogen).
WT1 expression calculations were normalized as the absolute ratio of
WT1 expression to normal ABL expression, so a value >1.0 is suggestive of
higher expression of WT1 compared with the normal population. Assays
were performed in replicates for greater accuracy in comparing results, and
when the ABL quantiﬁcation was inappropriately low, we repeated the
assay 3 times. To determine the signiﬁcant cut-off levels of WT1 expression
for survival outcomes at several time points, we used receiver operation
characteristic (ROC) curve analysis. The most signiﬁcant cut-off level was
determined at WT1 ¼ 1.0 at diagnosis (P ¼ .038), and this level was close to
the median value (the median value for 104 patients was 0.951). We
initially stratiﬁed patients by multiples of this level to analyze survival
outcomes. After treatments, the median WT1 expression decreased from
the diagnostic level of .951 to a median value of .02 (1.5-log reduction) until
before HSCT. At postinduction chemotherapy and pre-HSCT time points,
the most signiﬁcant WT1 expression cut-offs for OS and DFS were at the
level of 25% from the top. The signiﬁcant value was .156 at postinduction
chemotherapy (P < .001) and .050 at pre-HSCT (P ¼ .001), but we could not
determine a signiﬁcant cut-off at the post-HSCT time point.
These values are much lower than the normal ABL expression level of
1.0, but we stratiﬁed patients at these levels and analyzed survival outcomes
similarly. One more parameter calculated in this study was the log10 DR of
the WT1 expression level between diagnosis and each of 3 post-treatment
times (postinduction chemotherapy and pre- and post-HSCT). To deter-
mine the signiﬁcant level of DR, we once again used ROC curve analysis with
identiﬁcation of survival outcomes (P < .01), and the most signiﬁcant level
occurred at 1-log reduction. We also classiﬁed patients into 2 subgroups
showing DR  1-log and <1-log, respectively.Treatment
All 104 patients were treated with chemotherapy to induce remission.
Seventy-four patients (71.2%) were treated according to our standard
protocol, which consists of 3þ7 idarubicin (IDA) plus N4-behenoyl-1-b-D-
arabinofuranosyl cytosine (BHAC) [26]. Brieﬂy, IDA was administered daily
at a dose of 12 mg/m2 for 30 minutes intravenously on 3 consecutive days,
and BHAC was administered daily at a dose of 300 mg/m2 over a period of 4
hours on 7 consecutive days. Twelve patients (11.5%) were treated with 3þ7
IDA plus cytosine arabinoside (ARA-C) at a dose of 100 mg/m2 for 24 hours.
Fifteen patients (14.4%) older than age 60 years of poor performance status
were treated with low-dose ARA-C (20 mg/m2 twice daily) plus etoposide
(100 mg) for 14 days. Of the last 2 patients (1.9%), 1 was treated with
daunorubicin at a dose of 60 mg/m2 plus ARA-C and 1 was treated with
ﬂudarabine plus ARA-C.
After CR, 1 or 2 consolidation chemotherapies were administered;
otherwise, patients were treated with reinduction chemotherapy. Ninety
patients (86.5%) achieved CR within 2 cycles of chemotherapy, and 68
patients (65.4%) who had available an HLA-matched sibling, unrelated, or
haploidentical familial donor eventually underwent allogeneic HSCT. We
administered a myeloablative conditioning regimen consisting of cyclo-
phosphamide (120mg/kg) combinedwith 1320 cGy of total body irradiation
or busulfex (12.8 mg/kg). In the case of advanced age or poor performance
status with comorbidity, we considered a reduced-intensity conditioning
regimen consisting of busulfex (6.4 mg/kg) and ﬂudarabine (150 mg/m2)
with 400 cGy of total body irradiation. If the patient did not have an avail-
able allogeneic donor, we gave an autologous HSCT with a myeloablative
conditioning regimen consisting of ARA-C (9 g/m2), melphalan (100mg/m2),
and 1200 cGy of total body irradiation after 2 cycles of consolidation
chemotherapy that followed CR (n ¼ 8).
Statistical Analysis
The purpose of this study was to determine the prognostic value ofWT1
expression levels and WT1 DR at speciﬁc time points in the course of
treatment. Clinical information, including molecular markers, treatment
protocols, and survival outcomes, were obtained. Other clinical parameters,
including age, leukocyte count, and peripheral blood (PB) and BM blast
percentage at diagnosis, were treated as continuous variables. To determine
the signiﬁcantly sensitive and speciﬁc cut-off levels of WT1 expression and
WT1 DR for survival outcomes, we used ROC curve analysis. All categorical
Table 2
Baseline Characteristics According to WT1 Expression at Diagnosis and at Pre-HSCT in CN-AML
WT1 Expression at Diagnosis (n ¼ 104) WT1 Expression at Pre-HSCT (n ¼ 68)
<1* (n ¼ 52) 1* (n ¼ 52) P <.05* (n ¼ 51) .05* (n ¼ 17) P
Age, yr (range) 46.2 (15-75) 48.4 (18-74) .459 40.4 (15-66) 48.7 (30-61) .013*
Gender (male) 31 (59.6%) 29 (55.8%) .691 29 (56.9%) 9 (52.9%) .778
Leukocyte count, 106/L (median) 34,676 45,125 .302 40,258 28,315 .343
PB blast 46.8% 50.5% .596 49.3% 42.5% .523
BM blast 65.4% 75.3% .031* 69.0% 66.3% .688
Platelet count, 106/L (median) 77,480 97,860 .253 91,980 73,530 .372
Induction therapy .780 .716
Intensive chemotherapy 45 (86.5%) 44 (84.6%) 50 (98.0%) 17 (100%)
Low-dose chemotherapy 7 (13.5%) 8 (15.4%) 1 (2.0%) 0 (0.0%)
Disease status
CR after 1 cycle of chemotherapyy 43 (82.7%) 35 (67.3%) .070 46 (90.2%) 15 (88.2%) .818
CR within 2 cycles of chemotherapy 48 (92.3%) 42 (80.8%) .085 51 (100%) 51 (100% 1.000
Primary refractory 4 (7.7%) 10 (19.2%) .085 0 (0.0%) 0 (0.0%) 1.000
Relapse during chemotherapy 9 (17.3%) 8 (15.4%) .791 2 (3.9%) 2 (11.8%) .234
Final treatment plan
Chemotherapy alone 14 (26.4%) 22 (43.1%) .099
Intensive chemotherapy 9 (64.3%) 16 (72.7%) .592
Low-dose ARA-C 5 (35.7%) 6 (27.3%) .592
HSCT 38 (73.1%) 30 (57.7%) .099
Pre-HSCT status (non-CR) 4 (10.5%) 1 (3.3%) .169 3 (5.9%) 2 (11.8%) .421
Type
Auto-HSCT 6 (15.7%) 2 (6.6%) .246 6 (11.8%) 2 (11.8%) 1.000
Allo-MSD 19 (50.0%) 17 (56.6%) .584 25 (49.0%) 11 (64.7%) .262
Allo-unrelated 11 (28.9%) 8 (26.6%) .835 15 (29.4%) 4 (23.5%) .640
Haplo-identical 2 (5.4%) 3 (10.2%) .457 5 (9.8%) 0 (0.0%) .180
Source (BM) 15 (39.5%) 14 (46.6%) .552 23 (45.1%) 6 (35.3%) .479
Intensity (MAC) 31 (81.6%) 20 (66.6%) .159 39 (76.5%) 12 (70.6%) .628
Mutation status
NPM1 mutation 14 (26.9%) 22 (42.3%) .099 12 (23.5%) 7 (41.2%) .160
FLT3-ITD mutation 11 (21.2%) 19 (36.5%) .083 6 (11.8%) 5 (29.4%) .087
NPM1(þ) / FLT(e) 8 (15.4%) 12 (23.1%) .132 9 (17.6%) 4 (23.5%) .270
NPM1(e) / FLT(e) 33 (63.5%) 21 (40.4%) 36 (70.6%) 8 (47.1%)
NPM1(þ) / FLT(þ) 6 (11.5%) 10 (19.2%) 3 (5.9%) 3 (17.6%)
NPM1(e) / FLT(þ) 5 (9.6%) 9 (17.3%) 3 (5.9%) 2 (11.8%)
MSD indicates matched sibling donor; MAC, myeloablative conditioning regimen.
* Statisticallymost signiﬁcant cut-off values for bothOS andDFS analyzedbyROCcurve:WT1 at diagnosisj1.000 (median¼ .951, P¼ .038),WT1 at pre-HSCTj
.050 (25% level from the top ¼ .050, P ¼ .001).
y Remission induction chemotherapy regimens are as follows (WT1 < 1 versus 1, P ¼ .190): IDA/BHAC 3/7, n ¼ 74 (36 versus 38), IDV/ARA-C 3/7, n ¼ 12
(9 versus 3), daunorubicin þARA-C 3/7, n ¼ 2 (0 versus 2), ﬂudarabine þARA-C, n ¼ 1 (0 versus 1). Low-dose ARA-C (20 mg/m2 twice daily) for 14 days, n ¼ 15
(7 versus 8).
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continuous variables were compared using Student’s t-test and Wilcoxon’s
rank-sum test.
OS and DFS rates were calculated using Kaplan-Meier survival curves,
and log-rank analysis was used to evaluate differences between survival
distributions. OS represents the proportion of patients who were alive at
a speciﬁed time from the date of diagnosis and was associated with death
due to any cause, both related and unrelated to the AML and treatments. DFS
measured the proportion of people who remained alive or free of disease at
a speciﬁed time from the date of ﬁrst CR achieved and took into account
death, relapse, loss to follow-up, and transfer to hopeless status as the result
of disease or treatment complications. Univariate and multivariate analyses
using the Cox’s proportional regression model were used to calculate the
survival hazard ratio (HR). All statistical analyses were performed using SAS
software (version 9.2, SAS Institute, Inc., Cary, NC). Statistical signiﬁcance
was set at P < .05.
RESULTS
WT1 Expression and WT1 DR from Diagnosis to the HSCT
Period: Baseline Characteristics
In Table 1, serial RQ-PCR assays of WT1 expression from
diagnosis to post-HSCT are presented by quartile. The
median WT1 level at diagnosis was .951. Signiﬁcant diag-
nostic WT1 RQ-PCR cut-off levels for inferior OS and DFS
were determined at the level higher than 1.0 (close to the
median value, P ¼ .038). At postinduction chemotherapy and
pre-HSCT, medianWT1 expression levels were .022 and .019.
However, the most signiﬁcant WT1 RQ-PCR cut-off levels for
inferior OS and DFS were determined at the levels higherthan .15 and .05 (25% level from the top, P < .001 and
P ¼ .001) at postinduction chemotherapy and pre-HSCT
respectively. We could not obtain a signiﬁcant cut-off at the
post-HSCT time point.
Table 1 also shows the greater than 1-log post-treatment
WT1 DR. The maximal decreases in WT1 expression, up to
4-log, occurred after remission induction chemotherapy and
after HSCT. A median reduction of 1.5-log occurred after
induction chemotherapy and at pre-HSCT and a median
reduction of 2-log occurred in the post-HSCT period. The
most signiﬁcant WT1 DR for survival outcomes was deter-
mined at more than 1-log compared with the pretreatment
level at both postinduction chemotherapy (P< .001) and pre-
HSCT (P ¼ .003). Sixty-four patients (61.5%) at postinduction
chemotherapy, 46 patients (67.6%) at pre-HSCT, and 44
patients (75.9%) at post-HSCT achievedWT1 DR greater than
1-log.
Baseline characteristics of patients according to WT1
expression level at diagnosis and pre-HSCT are shown in
Table 2. Among 104 patients, 52 patients showed WT1
expression higher than 1.0, and the other 52 were lower than
1.0 at diagnosis. Between these 2 subgroups, age, leukocyte
count, platelet count, and PB blast percentage did not differ
signiﬁcantly, but the BM blast count was higher in the group
with higherWT1 expression at diagnosis (75.3% versus 65.4%,
P ¼ .031). The subgroup with lower WT1 expression at
Figure 1. (A) HigherWT1 expression  1.0 at diagnosis showed inferior OS and DFS (n ¼ 104, 52 versus 52). (B) HigherWT1 expression 0.15 (higher than upper 25%
level) at postinduction chemotherapy showed inferior OS and DFS (n ¼ 104, 52 versus 52). (C) HigherWT1 expression .05 (higher than upper 25% level) at pre-HSCT
showed inferior OS and DFS after HSCT (n ¼ 68, 17 versus 51).
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versus 57.7%, P¼ .099) and showed a relatively higher CR rate
after the ﬁrst cycle of induction chemotherapy (82.7% versus
67.3%, P ¼ .070). The 2 subgroups did not differ signiﬁcantly
in postinduction therapy and status of several mutations, but
FLT3-ITD mutations were more common in the subgroup
with higherWT1 expression at diagnosis (36.5% versus 21.2%,
P ¼ .083).
Sixty-eight patients treated with HSCT (5 patients were
non-CR at pre-HSCT) were divided into 2 subgroupsaccording to the pre-HSCT WT1 expression at .05 (25% level
from the top, higher than .05 [n ¼ 17] versus lower than .05
[n ¼ 51]). Patients were signiﬁcantly older in the subgroup
with higher WT1 expression at pre-HSCT (48.7 versus 40.4
years, P ¼ .013). Other parameters did not differ signiﬁcantly
between the 2 subgroups. As in the subgroup division based
on level at diagnosis, FLT3-ITD mutations were more
common in the subgroup with higher pre-HSCT WT1
expression (29.4% versus 11.8%, P ¼ .087), and we also iden-
tiﬁed slightlymoreNPM1mutations in the groupwith higher
J.-H. Yoon et al. / Biol Blood Marrow Transplant 19 (2013) 958e966962WT1 expression (41.2 versus 23.5%, P ¼ .160). Mutation
frequencies did not differ signiﬁcantly between 2 subgroups.
CN-AML Survival Outcomes Associated with WT1
Expression and WT1 DR from Diagnosis to the HSCT
Period
The patient subgroups with higher WT1 expression at
diagnosis, at postinduction chemotherapy and preceding
HSCT independently showed OS and DFS rates inferior to
those of the subgroup with lowerWT1 expression (Figure 1);
WT1 levels higher than 1.0 at diagnosis (n¼ 52 versus 52, P¼
.015 and P ¼ .006), higher than .15 at postinduction chemo-
therapy (n ¼ 26 versus 78, P < .001 and P < .001), and higher
than .05 preceding HSCT (n ¼ 17 versus 51, P ¼ .002 and
P ¼ .003) were signiﬁcantly predictive. The subgroup with
WT1 DR greater than 1-log at postinduction chemotherapy
(n ¼ 64 versus 40, P ¼ .009 and P ¼ .002) and at pre-HSCT
(n ¼ 46 versus 22, P ¼ .009 and P ¼ .003) showed more
favorable OS and DFS than the group with less than 1-log
reduction (Figure 2). Univariate and multivariate analyses
by Cox’s proportional regression model are presented in
Table 3. Both lowerWT1 expression at diagnosis andWT1 DR
more than 1-log at pre-HSCT predicted favorable survival
outcomes in multivariate analysis.
Subgroups were further selected according to the WT1
expression at diagnosis (1.0 or<1.0) andWT1DR (>1-log or
<1-log) preceding HSCT and analyzed for survival outcomes.
We identiﬁed four subgroups: Subgroup1 (n ¼ 20), WT1 at
diagnosis <1.0 and WT1 DR  1-log; Subgroup 2 (n ¼ 18),Figure 2. (A)WT1 DR more than 1-log at postinduction chemotherapy showed superio
also showed superior OS and DFS after HSCT (n ¼ 68, 46 versus 22).diagnostic WT1 < 1.0 and WT1 DR < 1-log; Subgroup 3 (n ¼
26), diagnosticWT11.0 andWT1DR 1-log; and Subgroup
4 (n ¼ 4), diagnosticWT1 1.0 andWT1 DR < 1-log. Patients
with higher diagnostic WT1 expression showed more than
1-log reduction in 86.6% of patients (Subgroup 3), and this
was signiﬁcantly higher than in the group with lower diag-
nosticWT1 expression (P ¼ .003): more than 1-log reduction
in 52.6% (Subgroup 1). Patients of lower WT1 expression at
diagnosis with more than 1-log reduction inWT1 expression
from diagnosis to pre-HSCT (Subgroup 1) comprised the
most favorable-risk group, with respect to OS (P¼ .002, HR¼
.029 [95% conﬁdence interval {CI}, .002-.263]) and DFS (P ¼
.002, HR ¼ .029 [95% CI, .003-.259]) after HSCT (Figure 3).
Subgroup 3, with higher WT1 expression at diagnosis and
more than 1-log reduction at the time of HSCT, showed more
favorable OS (P¼ .010, HR¼ .203 [95% CI, .060-.681]) and DFS
(P ¼ .031, HR ¼ .281 [95% CI, .089-.887]) than Subgroup 2
with less than 1-log reduction in WT1 expression from
diagnosis to pre-HSCT. All HRs of Subgroups 1, 2, and 3 were
compared with Subgroup 4, which presented the worst
survival outcomes.
Analysis in the Subgroup of NPM1-wild-type/FLT3-
ITDeNegative CN-AML
The NPM1-wild-type/FLT3-ITDenegative CN-AML sub-
group included 54 patients, and 44 of these were treated
with HSCT. Within this subgroup, patients with higher
WT1 expression at diagnosis and at postinduction chemo-
therapy showed inferior OS and DFS as compared withr OS and DFS (n ¼ 104, 64 versus 40). (B)WT1 DR more than 1-log at pre-HSCT
Table 3
Univariate and Multivariate Analyses of OS and DFS Calculated Using Cox’s Proportional Regression Model in CN-AML Patients Treated with HSCT (n ¼ 68)
OS DFS
Univariate Multivariate Univariate Multivariate
HR P (95% CI) HR P (95% CI) HR P (95% CI) HR P (95% CI)
Age, yr 1.010 .322 (.990-1.031) 1.007 .439 (.989-1.025)
Leukocyte (50,000) .971 .935 (.485-1.947) 1.009 .976 (.555-1.836)
BM blast (70%) 1.289 .439 (.678-2.451) 1.422 .227 (.803-2.519)
FLT3-ITD positivity 4.064 <.001* (2.128-7.761) 4.129 <.001* (2.358-7.229)
Higher WT1  1.0 at diagnosis
(median)
2.180 .019* (1.138-4.175) 4.257 .010* (1.421-12.752) 2.138 .008* (1.218-3.753) 3.519 .010* (1.343-9.220)
Higher WT1  .15 at postinduction
chemotherapy (upper 25%)
4.857 <.001* (2.498-9.442) 6.478 <.001* (3.651-11.492)
Higher WT1  .05 at pre-HSCT
(upper 25%)
3.841 .003* (1.593-9.264) 3.182 .004* (1.439-7.036)
WT1 DR  1-log at pre-HSCT .310 .009* (.128-.751) .154 .001* (.053-.445) .325 .005* (.148-.715) .174 <.001* (.068-.441)
* P < 0.05.
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patients with higher than 1.0 at diagnosis (n ¼ 21 versus 33,
P ¼ .080 and P ¼ .010) and higher than .15 at postinduction
chemotherapy (n ¼ 7 versus 47, P ¼ .027 and P ¼ .001).
Patients with WT1 DR greater than 1-log at pre-HSCT
also showed more favorable OS (P ¼ .048) and DFS (P ¼
.060) after HSCT than did those withWT1 DR less than 1-log
(Figure 4C).
DISCUSSION
As reported in previous studies, BM and PB samples ob-
tained from healthy volunteers express WT1 at very low
levels [27,28]. We also found that WT1 is overexpressed in
most AML patients at diagnosis, and various decremental
responses were observed along the timeline of the treat-
ments, including HSCT. A number of studies have pointed to
this consistently overexpressed gene as a potential target for
new immunological therapies for CN-AML, using WT1 gene
expression as a marker for MRD assessment [17,29]. Evalu-
ation of MRD after the ﬁrst cycle of induction chemotherapy
is helpful in predicting outcome and may inform the selec-
tion of postremission treatment type and intensity. At times
before and after HSCT, MRD evaluation is important for early
detection of relapse, and based on this evaluation, the
conditioning regimen intensity or immunosuppressive
agents for post-HSCT management may be adjusted. OurFigure 3. Subgroup analyses associated with relations between diagnostic WT1 expre
WT1 < 1.0 and WT1 DR  1-log; Subgroup 2 (n ¼ 18), diagnostic WT1 < 1.0 and WT1
Subgroup 4 (n ¼ 4), diagnostic WT1 1.0 and WT1 DR < 1-log. Subgroup 1 showed th
than Subgroup 2.present ﬁndings support the use of WT1 expression as an
MRD marker in CN-AML and as a predictive indicator of
survival outcomes. These ﬁndings are especially relevant
because adult patients with NPM1-wild-type/FLT3-ITDenegative
CN-AML comprise the largest subgroup in adult CN-AML.
Evidence increasingly supports using WT1 expression
levels fromBM or PB as anMRDmarker at diagnosis and after
treatments. Cilloni et al. reported that increased WT1
expression from PB samples probably represents a circu-
lating blast cell population proportional to the leukemia
burden and may therefore serve as an early predictor of
relapse after treatments [17,30]. Using BM and PB samples
from 96 adult AML patients with variable cytogenetic risk,
Gray et al. found signiﬁcant association of WT1 expression
from PB with BM blast counts but not with peripheral
leukocyte counts. These authors also showed the utility of
using PB samples forWT1 analysis in detecting MRD [16]. We
used only BM for assays of WT1 expression in samples from
104 adult CN-AML patients and found a BM blast count that
was statistically higher in the group with higher WT1
expression at diagnosis.
The signiﬁcance of either WT1 mutation or expression
level at diagnosis for OS or leukemia-free survival in CN-AML
remains uncertain [16,19,30,31]. In contrast, changes in WT1
expression in the course of treatment may prove to be more
informative. In the present study, increases in WT1ssion and WT1 DR at pre-HSCT. Four subgroups: Subroup1 (n ¼ 20), diagnostic
DR < 1-log; Subgroup 3 (n ¼ 26), diagnostic WT1  1.0 and WT1 DR  1-log;
e most favorable outcomes. Subgroup 3 showed more favorable survival curves
Figure 4. WT1 expression analysis in the NPM1-wild-type/FLT3-ITDenegative CN-AML. (A) Higher WT1 expression at diagnosis showed inferior OS and DFS. (B)
HigherWT1 expression at postinduction chemotherapy also showed inferior OS and DFS. (C)WT1 DR more than 1-log also showed superior OS and DFS after HSCT in
the NPM1-wild-type/FLT3-ITDenegative CN-AML subgroup.
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period were independently associated with inferior OS and
DFS. The WT1 DR at pre-HSCT showed power to predict
survival outcomes after HSCT. AWT1 DR > 1-log (median ¼
1.5-log) after the ﬁrst cycle of induction chemotherapy and at
pre-HSCT predicted favorable outcomes. Previous studies
reported that failure to reduction of at least 2-log units
compared with pretreatment level independently predicted
more relapse [16,17]. In a study of 91 patients with subtype or
karyotype not speciﬁed, Cilloni et al. found that a reduction
in WT1 expression of at least 2-log compared with the
pretreatment level after the ﬁrst cycle of chemotherapy
corresponded to a decreased risk of subsequent relapse. Atbaseline, WT1 expression levels in these patients exceeded
2  104 copies per 104 copies of ABL (corresponding to the
value of 2.0 in our study) [17], and this allowed better
discrimination of log reductions in expression. However, our
study targeted only CN-AML and included patients withWT1
expression levels both lower (<1.0) and higher (1.0) than
the level at diagnosis. The data showed that a reduction in
expression greater than 1-log from pretreatment up to HSCT
was signiﬁcantly and positively associated with favorable OS
and DFS after HSCT.
Important for the purpose of predicting survival after
HSCT, the analysis by subgroup showed that theWT1DR from
diagnosis up to HSCT predicted survival outcomes after HSCT
J.-H. Yoon et al. / Biol Blood Marrow Transplant 19 (2013) 958e966 965more accurately than did the level of WT1 expression at
diagnosis. Even for patients with lower WT1 expression at
diagnosis, a decrease of less than 1-log by the time of HSCT
predicted less favorable outcomes than decreases greater
than 1-log. Similarly, among patients with higher WT1
expression at diagnosis, a reduction of more than 1-log up to
the time ofHSCT predictedmore favorable survival outcomes.
This result justiﬁes the quantitative monitoring of changes in
WT1 expression inparallelwith chemotherapy to evaluate the
feasibility ofHSCT for patientswithCN-AML. For this purpose,
however, the factors that inﬂuence treatment-related reduc-
tion ofWT1 expression must be investigated.
To simplify the search for a reliable marker of residual
disease in adultwith CN-AML,we sought a subgroupwith the
lowestpossibleprevalenceof speciﬁcmutations. Thus, for this
study we selected adult patients with NPM1-wild-type/FLT3-
ITDenegative CN-AML. Patients with this combination
comprise the largest subgroup of adult CN-AML and are
classiﬁed as having intermediate-1 risk based on the Euro-
pean Leukemia Net guidelines. Patients with NPM1-
wild-type/FLT3-ITDepositive and NPM1-mutated/FLT3-ITDe
positive CN-AML share this classiﬁcation, whereas the
NPM1-mutated/FLT3-ITDenegative CN-AML is classiﬁed as
havingmore favorable risk [25]. For these intermediate-1 risk
group patients, the relevant prognostic factors remain to be
fully elucidated. However, in those in the NPM1-wild-type/
FLT3-ITDenegative CN-AML category, we found that low
WT1 expression at diagnosis andWT1 DR more than 1-log at
pre-HSCT may have favorable implications for OS and DFS
after HSCT.
Our study is limited by the retrospective design, partic-
ularly by the progressive loss of some data for the post-HSCT
period. The study is noteworthy, however, in that consis-
tently signiﬁcant results were observed at several stages in
the treatment of CN-AML. Overall, the ﬁndings support use of
WT1 expression as a marker of residual disease and under-
score the importance of WT1-based MRD kinetics in moni-
toring and treatment of CN-AML.
In conclusion, serial monitoring of WT1 expression of BM
in the time from diagnosis to the HSCT period may predict
survival outcomes in adult CN-AML. Even at the very low
levels detected during follow-up,WT1 expression and kinetic
properties of expression analyzed as the WT1 DR have
important implications. Speciﬁcally in NPM1-wild-type/
FLT3-ITDenegative adult CN-AML, WT1 expression at diag-
nosis and the WT1 DR determined before HSCT may predict
survival outcomes after HSCT.ACKNOWLEDGMENTS
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